CJC-1295

CJC-1295 is a 30-amino acid synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH), belonging to the GHRH-analog class of secretagogues. The compound was originally developed by ConjuChem Biotechnologies and is distinguished by a drug affinity complex (DAC) modification — a maleimidopropionic acid (MPA) linker that enables covalent binding to circulating albumin following subcutaneous administration. This modification is the defining pharmacological feature separating CJC-1295 DAC from the non-DAC variant (also marketed as modified GRF 1-29 or 'CJC-1295 without DAC'), which has a substantially shorter half-life of roughly 30 minutes. The DAC formulation extends plasma half-life to approximately 6–8 days, enabling once- or twice-weekly dosing in research protocols. For educational purposes only — this content is a research summary, not medical advice.

Mechanistically, CJC-1295 binds to and activates the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. This stimulates synthesis and pulsatile release of endogenous growth hormone, which in turn drives hepatic production of insulin-like growth factor 1 (IGF-1). Unlike exogenous recombinant human growth hormone (rhGH), CJC-1295 does not suppress the hypothalamic-pituitary axis in the same direct manner — it amplifies the amplitude of existing GH pulses rather than replacing them. The DAC modification allows the molecule to persist in circulation while bound to albumin, releasing slowly and maintaining receptor stimulation over an extended window.

The strongest available evidence comes from a Phase II human trial published by Ionescu and Frohman (2006) in the Journal of Clinical Endocrinology & Metabolism. In this randomized, placebo-controlled study of 64 healthy adult subjects, single subcutaneous injections of CJC-1295 (at doses ranging from 30 to 120 mcg/kg) produced dose-dependent increases in mean GH concentrations by 2- to 10-fold and sustained IGF-1 elevations of 1.5- to 3-fold above baseline, with effects persisting for up to 14 days post-injection. Multiple-dose cohorts showed cumulative IGF-1 elevations maintained over several weeks. This constitutes the most robust human-trial data available for the compound and is frequently cited in research contexts. Animal model studies corroborate the GH/IGF-1 axis stimulation findings, with rodent studies demonstrating increased lean mass and reduced adiposity in GH-deficient models. Anecdotal reports from self-experimenting users commonly describe improved sleep quality, increased lean body composition over multi-week protocols, and accelerated recovery — these reports are uncontrolled and should not be interpreted as clinical evidence.

Dosing ranges reported in published human research contexts include single doses of 30–120 mcg/kg body weight, with the Phase II study referenced above using this range for pharmacokinetic characterization. In self-reported community protocols, fixed doses of 1,000–2,000 mcg once or twice weekly are frequently cited for the DAC formulation. These ranges are reported strictly for informational purposes as observed in research literature and user documentation — they do not constitute a recommendation or endorsement for human use. CJC-1295 is a research chemical; any human self-administration occurs entirely outside approved medical frameworks.

Legally, CJC-1295 occupies the status of an unscheduled research chemical in the United States — it is not a DEA-controlled substance, but neither is it FDA-approved for any indication, meaning human use exists in a gray regulatory space. In the UK, it is similarly unscheduled under the Misuse of Drugs Act but is not MHRA-approved. In Australia, peptides including GHRH analogs fall under Schedule 4 (Prescription Only Medicine) or Schedule 9 (Prohibited Substance) classifications depending on context, making unsupervised acquisition legally problematic. The EU treats it as an unapproved research compound. Sourcing considerations are material: reputable research chemical vendors should provide HPLC and mass spectrometry certificates of analysis (COA) from third-party laboratories confirming peptide identity, purity (typically ≥98% for research-grade), and absence of bacterial endotoxins. Vendors who cannot produce traceable third-party COAs, who do not require age verification, or who market products with explicit human-use health claims are red flags. The DAC vs. non-DAC distinction is frequently confused or mislabeled in vendor listings — confirming molecular weight via COA (CJC-1295 DAC: ~4.4 kDa with linker; modified GRF 1-29: ~3.3 kDa) is a practical verification step.